Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OPK
stocks logo

OPK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
139.76M
-23.88%
-0.068
-777%
130.80M
-12.74%
-0.060
-40%
137.18M
-12.52%
-0.058
-69.47%
Estimates Revision
The market is revising Downward the revenue expectations for OPKO Health, Inc. (OPK) for FY2025, with the revenue forecasts being adjusted by -6.78% over the past three months. During the same period, the stock price has changed by 0.00%.
Revenue Estimates for FY2025
Revise Downward
down Image
-6.78%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-9.77%
In Past 3 Month
Stock Price
No Change
down Image
0.00%
In Past 3 Month
Wall Street analysts forecast OPK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPK is 2.75 USD with a low forecast of 2.25 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast OPK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPK is 2.75 USD with a low forecast of 2.25 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.350
sliders
Low
2.25
Averages
2.75
High
3.00
Current: 1.350
sliders
Low
2.25
Averages
2.75
High
3.00
JPMorgan
Neutral
initiated
2025-11-20
Reason
JPMorgan
Price Target
2025-11-20
initiated
Neutral
Reason
JPMorgan initiated coverage of Opko Health with a Neutral rating and no price target. The firm says Opko is a "multi-faceted" healthcare company, focusing in clinical diagnostics services through BioReference Labs operations and therapeutics development through its ModeX subsidiary. The company's clinical-stage pipeline portfolio remains early stage and needs clinical validation before "buy-in from investors," the analyst tells investors in a research note. JPMorgan awaits clinical validation before recommending the shares.
Jefferies
Buy
to
Hold
downgrade
$2
2025-10-30
Reason
Jefferies
Price Target
$2
2025-10-30
downgrade
Buy
to
Hold
Reason
Jefferies downgraded Opko Health to Hold from Buy with a price target of $1.60, down from $2. The firm, which is lowering Ngenla out-year estimates, says Opko's drug pipeline has potential, but is still early with a need for clarity on catalysts.
JPMorgan
Neutral
initiated
2025-04-25
Reason
JPMorgan
Price Target
2025-04-25
initiated
Neutral
Reason
JPMorgan initiated coverage of Opko Health with a Neutral rating and no price target. Following a series of asset sales and monetizing transactions, Opko is closing in on its goal of becoming a self-funded biotech company, the analyst tells investors in a research note. However, the firm believes it will take a series of clinical wins to gain broader investor recognition, with shares likely to trade range-bound over the mid-term.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2025-04-07
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-04-07
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2025-03-19
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-03-19
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2025-03-12
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-03-12
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for OPKO Health Inc (OPK.O) is -5.54, compared to its 5-year average forward P/E of 83.66. For a more detailed relative valuation and DCF analysis to assess OPKO Health Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
83.66
Current PE
-5.54
Overvalued PE
443.51
Undervalued PE
-276.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-20.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
15.77
Undervalued EV/EBITDA
-57.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.72
Current PS
0.00
Overvalued PS
2.11
Undervalued PS
1.33
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 1295.35% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1498.79% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 1295.35% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

OPK News & Events

Events Timeline

(ET)
2025-10-29
16:32:53
Opko Health Announces Q3 EPS of 3 Cents, Below Consensus Estimate of 5 Cents
select
2025-10-29
08:09:58
Opko Health's ModeX Forms Licensing and Collaboration Partnership with Regeneron
select
2025-10-28 (ET)
2025-10-28
08:15:49
Opko Health's ModeX Therapeutics Launches MDX2004 Clinical Trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-22NASDAQ.COM
Insider Buying Update for Friday, November 21: GLOO, OPK

  • GLOO Insider Purchase: Patrick P. Gelsinger bought 125,000 shares of GLOO at $8.00 each, totaling $1M, and is currently up 17.6% based on a trading high of $9.41.

  • OPKO Health Insider Purchase: CEO Phillip Frost purchased $759,115 worth of OPKO Health, acquiring 580,000 shares at $1.31 each, marking his 18th purchase in the past year, totaling $6.27M at an average of $1.45 per share.

  • Market Performance: GLOO's stock is up about 2.2% on Friday, while OPKO Health is trading up approximately 2.3% on the same day.

  • Disclaimer: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

[object Object]
Preview
9.5
11-13PRnewswire
NextPlat Reports Third Quarter 2025 Results

  • Financial Performance: NextPlat Corp reported Q3 2025 revenue of approximately $13.8 million, a decrease from $15.4 million in Q3 2024, primarily due to a decline in healthcare operations. However, the company anticipates improved performance in Q4 2025 driven by increased prescription volumes and cost-cutting measures.

  • Cost-Cutting Initiatives: The company has successfully reduced operating expenses to approximately $4.7 million in Q3 2025, down from $7.8 million in the previous year, through staff reductions and operational efficiencies, which are expected to contribute to further improvements in financial metrics.

  • Healthcare Segment Growth: NextPlat's healthcare segment is experiencing a resurgence with increased prescription volumes, particularly in the 340B program, and the addition of new customers, which is expected to drive significant revenue growth in the upcoming quarters.

  • E-Commerce Developments: The e-commerce division continues to perform well, particularly in satellite-based connectivity and IoT products, with ongoing expansion in sales channels and new product launches, including a marketing campaign for Florida Sunshine products in China.

[object Object]
Preview
4.0
11-01Benzinga
Jefferies Lowers OPKO Health Rating to Hold and Reduces Price Target to $1.6

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.

  • Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is OPKO Health Inc (OPK) stock price today?

The current price of OPK is 1.35 USD — it has decreased -1.46 % in the last trading day.

arrow icon

What is OPKO Health Inc (OPK)'s business?

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

arrow icon

What is the price predicton of OPK Stock?

Wall Street analysts forecast OPK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPK is 2.75 USD with a low forecast of 2.25 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is OPKO Health Inc (OPK)'s revenue for the last quarter?

OPKO Health Inc revenue for the last quarter amounts to 151.67M USD, decreased -12.65 % YoY.

arrow icon

What is OPKO Health Inc (OPK)'s earnings per share (EPS) for the last quarter?

OPKO Health Inc. EPS for the last quarter amounts to 0.03 USD, decreased -25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for OPKO Health Inc (OPK)'s fundamentals?

The market is revising Downward the revenue expectations for OPKO Health, Inc. (OPK) for FY2025, with the revenue forecasts being adjusted by -6.78% over the past three months. During the same period, the stock price has changed by 0.00%.
arrow icon

How many employees does OPKO Health Inc (OPK). have?

OPKO Health Inc (OPK) has 2997 emplpoyees as of December 05 2025.

arrow icon

What is OPKO Health Inc (OPK) market cap?

Today OPK has the market capitalization of 1.04B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free